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An oncogenic role of sphingosine kinase
Pu Xia, Jennifer R. Gamble*, Lijun Wang, Stuart M. Pitson, Paul A.B. Moretti,
Binks W. Wattenberg, Richard J. D’Andrea and Mathew A. Vadas*
Sphingosine kinase (SphK) is a highly conserved lipid
kinase that phosphorylates sphingosine to form
sphingosine-1-phosphate (S1P). S1P/SphK has been
implicated as a signalling pathway to regulate diverse
cellular functions [1–3], including cell growth,
proliferation and survival [4–8]. We report that cells
overexpressing SphK have increased enzymatic activity
and acquire the transformed phenotype, as determined
by focus formation, colony growth in soft agar and the
ability to form tumours in NOD/SCID mice. This is the
first demonstration that a wild-type lipid kinase gene
acts as an oncogene. Using a chemical inhibitor of
SphK, or an SphK mutant that inhibits enzyme
activation, we found that SphK activity is involved in
oncogenic H-Ras-mediated transformation, suggesting
a novel signalling pathway for Ras activation. The
findings not only point to a new signalling pathway in
transformation but also to the potential of SphK
inhibitors in cancer therapy.
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Results and discussion
To investigate the oncogenic role of SphK, non-trans-
formed NIH3T3 fibroblasts were transfected with human
SphK cDNA, which was recently cloned in our laboratory
[9]. Pooled stable transfectants (referred to as SK-3T3)
were used to avoid the phenotypic artefacts that may arise
from the selection and propagation of individual clones
from single transfected cells. In the SK-3T3 cell pools,
SphK activity was increased by over 600-fold (Figure 1a) in
comparison to NIH3T3 cells that were transfected with
the empty vector (N-3T3). Immunoblot analysis showed a
specific protein band with an apparent molecular weight
consistent with the predicted size of FLAG epitope-tagged
human SphK, which was detected only in the SK-3T3
pools but absent in N-3T3 cells (Figure 1a, inset). Intracel-
lular levels of S1P, the direct product of SphK, were
increased in SK-3T3 cells by 5.9 ± 0.9-fold, indicating that
SphK was activated constitutively in the stable transfec-
tants (Figure 1a). Although there was a wide range of SphK
expression levels (increases of between 12-fold and ~800-
fold) in different clones of transfected cells, intracellular
levels of S1P were increased by only between 4-fold and
~8-fold. Thus, S1P levels did not correlate with the expres-
sion levels of SphK, assayed by in vitro enzyme activity.
This may have been an influence of the availability and/or
subcellular location of sphingosine, and rapid degradation
of S1P by S1P phosphatase or S1P lyase. Despite notable
increases in intracellular levels of S1P, there was no
detectable S1P secretion into the extracellular media (data
not shown), which is consistent with a previous report
showing that overexpression of SphK in NIH3T3 or
HEK293 cell lines were unable to secrete S1P [8]. 
The growth curves of SK-3T3 cells were significantly dif-
ferent from those of control cells (Figure 1b). Overexpres-
sion of SphK dramatically enhanced cell growth in media
containing either 1% or 10% serum. Even in serum-free
medium for up to 7 days, SK-3T3 cells survived and grew
whereas the N-3T3 cells were dying. Furthermore, when
the cells reached saturation density, SK-3T3 cells contin-
ued to proliferate (see Supplementary material), suggest-
ing an escape from contact inhibition. Treatment of
SK-3T3 cells with a specific inhibitor of SphK, N,N-
dimethylsphingosine (DMS), significantly diminished the
enhanced proliferation induced by overexpression of
SphK, whereas DMS had no effect on proliferation of N-
3T3 cells (Figure 1c). These results suggest that the con-
stitutive activation of SphK in cells stably transfected with
SphK reduces two key growth-limiting properties: serum
dependence and contact inhibition.
The transforming activity assayed by focus formation in
NIH3T3 cells showed that cells transfected with SphK
but not empty vector induced numerous foci (Table 1
and Figure 2a). Both SphK and control vectors displayed
similar efficiency in the generation of G418-resistant
colonies (data not shown), indicating that the transform-
ing activity was not a non-specific effect of transfection.
Furthermore, SK-3T3 cells formed vigorous colonies in
soft agar (Table 1 and Figure 2b), revealing the acquisi-
tion of anchorage-independent growth. Although N-3T3
cells exhibited a low background level of colony forma-
tion, which may be due to spontaneous transformation,
overexpression of SphK resulted in a 20–50-fold increase in
the number of colonies and an obvious increase in colony
size. Two randomly selected clones of SphK-transfected
cell lines, KT-2 and KT-5, showed a similar transforming
capacity although KT-2 had a 50-fold higher expression
level than KT-5 (see Supplementary material). Impor-
tantly, DMS inhibited the transforming capacity of SphK
in a dose-dependent manner, with 2.5 µM DMS resulting
in total reversion to the normal phenotype (Figure 2b), sug-
gesting that the activity of the enzyme is essential for the
transforming process. Moreover, overexpression of a mutant
SphK, SphKG82D, which lacks enzymatic activity [10]
failed to induce transformation (Figure 2a). Taken
together, these results suggest that it is the activation of
SphK, which results in increased S1P levels, rather than
the overexpression itself that is responsible for the trans-
forming capacity of this enzyme. 
In addition to the intracellular function of S1P, the sig-
nalling role of SphK is also mediated by the binding of
S1P to membrane G-protein-coupled receptors (Edg
family), mainly in a pertussis-toxin-sensitive manner [1,2].
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Table 1
Transforming activities and tumorigenicity in transfected NIH3T3 cells.
Foci Colonies in soft agar Tumorigenicity
Cell line – PTX + PTX Number Size (mm) (tumours per injection)
N-3T3 1.8 ± 1.5 0.8 ± 0.6 3.3 ± 2.1 < 0.1 0/3
SK-3T3 49 ± 7.5 41.2 ± 13.2 122.3 ± 17.6 0.1–0.45 9/9
For the focus-formation assay, low-passage NIH3T3 cells were
transfected with SphK (SK-3T3) or empty vector (N-3T3); 2 days later,
the transfected cells were seeded to six-well plates. After reaching
confluence, the cells were cultured for 3 weeks in DMEM containing
5% FCS in the presence or absence of pertussis toxin (PTX,
50 ng/ml). The foci were scored after staining with 0.5% crystal violet.
For the soft-agar assay, suspensions of 1 × 104 cells from the stably
transfected SK-3T3 or N-3T3 cells in a growth medium containing
0.33% agar were overlaid onto 0.6% agar gel. After 21 days
incubation, colonies were stained with 0.1 mg/ml MTT and scored.
Results shown are the mean ± SD from 3–5 experiments done in
duplicate or triplicate. For the tumourigenesis assay, 4–6-week-old
NOD/SCID mice were injected subcutaneously with 5 × 105 cells from
various lines (see Supplementary material), in 200 µl sterile PBS.
Animals were examined twice per week and tumours were measured
after 4 weeks. 
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Overexpression of SphK stimulates proliferation in NIH3T3 cells.
(a) Cytosolic SphK activity (light grey bars) and intracellular S1P levels
(dark grey bars) were measured in the cells stably transfected with a
plasmid expressing FLAG epitope-tagged SphK (SK-3T3) or empty
vector alone (N-3T3) as described previously [9]. SphK activity was
measured by incubating the cytosolic fraction with 5 µM sphingosine
dissolved in 0.1% triton X-100 and [γ-32P]ATP (1 mM, 0.5 mCi/ml) for
15 min at 37°C as described previously [16]. For assays of intracellular
S1P levels, cells were labelled with [3H]sphingosine (1 µM, 2 µCi/ml)
for 30 min, and radioactivity incorporated into cellular lipids was
extracted; [3H]S1P was then resolved by thin-layer chromatography
(TLC) with 1-butanol/methanol/acetic acid/water (8:2:1:2,
volume/volume), visualised and quantified as described previously [8].
The inset shows expression of FLAG-tagged SphK in transfected cells
by an immunoblot assay probed with anti-FLAG monoclonal antibodies
(M2, Kodak). (b) Stably transfected SK-3T3 (shaded circles) or N-3T3
cells (unshaded circles) were plated in 48-well plates (1,000 cells per
well) in DMEM containing 10% FCS. After 8 h, the cells were washed
twice with DMEM and then grown in DMEM containing 1% or 10%
FCS, or serum-free medium (DMEM containing 0.1% BSA). At the
indicated times, cells were counted in a haemocytometer or by a
thiazolyl blue (MTT) assay as described previously [7]. (c) Equal
numbers of N-3T3 and SK-3T3 cells were plated. After a 5 day
incubation in the presence or absence of DMS (2.5 µM), cell number
was counted. Medium was replaced every day. Values are the
mean ± SD from more than three experiments.
Indeed, some of the biological responses to S1P have been
reported to be inhibited by pertussis toxin [5,11,12].
However, the presence of pertussis toxin (50 ng/ml) had
no effect on the transforming activity of SphK (Table 1),
which is consistent with the previous report that pertussis
toxin does not suppress cell growth in SphK-transfected
fibroblasts [8]. Furthermore, the inhibitory effect of DMS
on the transformation, along with the observation that SK-
3T3 cells were unable to secrete S1P into media, do not
support an extracellular role for S1P in mediating cell
transformation induced by overexpression of SphK.
When SphK-transfected NIH3T3 cells from either stable
transfectant pools or selected clones were injected subcu-
taneously into NOD/SCID mice, tumours became appar-
ent at the site of injection within 3–4 weeks (Table 1 and
Figure 2c). No mice injected with the control cells induced
tumours during 10 weeks of observation. The histological
appearance of tumour sections displayed the morphology
of fibrosarcoma with many mitotic figures (Figure 2c).
Western blot analysis of extracts derived from tumours
showed high levels of FLAG-tagged protein (Figure 2d),
revealing that the neoplastic cells retain and express the
SphK transgenes. Thus, the tumours developed from the
injected SphK-transfected cells but not from sponta-
neously transformed NIH3T3 cells. 
Given the ability of SphK to transform cells, the potential
role of SphK in the well-documented oncogene-induced
transformation was explored. When NIH3T3 cells were
transfected with an activated mutant H-Ras (V12-Ras),
SphK activity was significantly increased to 198 ± 32% in
comparison with the parental cells (Figure 3a). In contrast,
cells transfected with v-Src (Figure 3a) or dominant-negative
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Figure 2
Cells overexpressing SphK are transforming
and tumourigenic. (a) Focus-formation assay
in NIH3T3 cells transfected with SphK,
SphKG82D, or vector alone as described in
Table 1. (b) N-3T3 and SK-3T3 cells were
cultured on soft agar and fed with medium
containing various concentrations of DMS
every 2 days. Colonies were stained with MTT
and photographed after 3 weeks of
incubation. (c) Morphology of a paraffin-fixed
tumour section stained with hematoxylin and
eosin (100 × magnification) and a photograph
of tumours (inset) in NOD/SCID mice injected
with SK-3T3 cells. (d) Whole cell extracts
from three individual tumours (lanes 4–6) and
respective peripheral tissues (lanes 1–3) and
N-3T3 (lane 7) or SK-3T3 cells (lane 8) were
analysed by western blotting. The upper blot
was probed with anti-FLAG and the bottom
with anti-actin antibodies.
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Figure 3
SphK activation is involved in Ras
transformation. (a) NIH3T3 cells were
transfected with the indicated vectors and
SphK activity was measured 48 h after
transfection. (b) Focus-formation assays were
performed in the presence or absence of
DMS (2.5 µM), or in cells cotransfected with
V12-Ras plus SphKG82D, and v-Src plus
SphKG82D. Values are the mean ± SD from
more than three experiments.
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Ras (N17-Ras, data not shown) had no changes in SphK
activity, suggesting a specific involvement of SphK in the
Ras-activated pathway. Moreover, when the cells were
treated with DMS, the focus formation was reduced by
41 ± 4% (p < 0.0001) in V12-Ras-transfected cells, but not
in v-Src-transfected cells (Figure 3b), indicating that Ras
transformation requires SphK activation. The inability of
DMS to inhibit v-Src transformation rules out non-specific
effects or a general toxicity resulting from the inhibition of
SphK. To further confirm the role of SphK in Ras transfor-
mation, we used SphKG82D, which is a dominant-negative
mutant that not only lacks kinase activity but also blocks
agonist-stimulated activation of endogenous SphK [10].
When V12-Ras was cotransfected with SphKG82D, the
Ras-induced SphK activation was completely inhibited
(Figure 3a) and the transforming ability of Ras was also
significantly reduced (Figure 3b, p < 0.0001). Again v-Src-
induced transformation was not inhibited by SphKG82D
(Figure 3b). Thus, SphK not only possesses transforming
potential of its own right, as demonstrated by overexpres-
sion, but is also involved in Ras-mediated transformation. 
The events downstream from activation of SphK that
promote transformation are unclear but could include
protection from apoptosis and acceleration of cell-cycle
progression. Previous work has shown that increased intra-
cellular S1P by overexpression of SphK expedites the
G1–S transition and promotes cell growth in low-serum
media [8]. Agonist-stimulated endogenous SphK activation
protects against cell death [5–7]. Inhibition of DEVDase
activity and caspase-3 activation by SphK is likely to relate
to its anti-apoptotic effect [5,6]. The effect of SphK on
cell survival and growth is evolutionarily conserved [13,14],
indicating the importance of SphK in regulating cell
growth from yeast to mammals.
The oncogenic effect of SphK and its involvement in Ras
transformation indicate a novel signalling pathway in cel-
lular transformation and provide a potential link between
sphingolipids and mammalian tumour pathogenesis. Inter-
estingly, there is a recent report that S1P levels are signifi-
cantly increased in the ascitic fluids of patients with
ovarian cancer [15]. The importance of constitutive SphK
activation in transformation also raises the possibility of
using SphK inhibitors in cancer therapy. 
Supplementary material
Supplementary material including growth of transfected cells at satura-
tion density, transforming activity of SphK-transfected clones and a table
showing tumorigenesis of NOD/SCID mice after injection of transfected
cells is available at http://current-biology.com/supmat/supmatin.htm.
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